{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:51:05Z","timestamp":1787028665463,"version":"build-2736575974"},"reference-count":41,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Advances in the genetic understanding of pheochromocytoma\u2013paraganglioma (PPGL) have considerably refined personalized approaches to diagnosis and management. This study aims to present our institutional experience on the diagnostic characteristics, clinical course, and genetic background of patients with PPGL, in the context of the current literature. Methods: This retrospective analysis included 35 patients diagnosed with PPGL between years 2020 and 2024, all of whom underwent surgical resection and next-generation sequencing for germline mutations in major PPGL susceptibility genes. Clinical presentation, biochemical profile, pathological findings, and follow-up outcomes were compared between mutation-positive and mutation-negative cases. Results: Of the 35 patients with PPGL, germline mutations were identified in 6 patients (17%): 2 in Cluster 1A genes (SDHA, SDHB), 2 in Cluster 1B (VHL), and 2 in Cluster 2 (NF1). Consistent with existing literature, pathogenic germline variants\u2014particularly SDHB and VHL\u2014were identified in our cohort exclusively in patients younger than 30 years (ages 17, 20, and 25). Mutation-positive patients more frequently exhibited noradrenergic or non-secretory profiles (p = 0.01). Among the three non-secretory tumors in the cohort, two harbored genetic mutations (SDHA, NF1). Interestingly, both NF1-positive patients were normotensive\u2014one (c.3496G &gt; A) with a non-secretory tumor and the other (c.2329T &gt; A) presenting at an unusually late age (63 years)\u2014a strikingly atypical spectrum that underscores the phenotypic variability of NF1-associated PPGL. Bilateral disease was observed exclusively in VHL carriers (p = 0.03). Importantly, we identified a rare VHL c.369delG frameshift variant, not previously reported in association with PPGLs, in a patient with PPGL. No significant difference was observed between SDHB loss (p = 0.1) and proliferative indices (mitotic count, Ki-67) (p = 0.07, p = 0.6) between the two groups. During a median follow-up of 24 months (IQR: 18\u201336), one SDHB-positive patient had a recurrence, while no distant metastases were detected in the remaining mutation carriers. Conclusions: These findings support characteristic clinical patterns among mutation-positive PPGL and underscore the importance of systematic germline testing in all cases\u2014irrespective of age, family history, or biochemical profile\u2014to guide individualized management and enable cascade screening. The identification of a rare VHL c.369delG variant, previously unreported in association with PPGL, within a characteristic VHL-related clinical phenotype highlights the importance of this association. Similarly, atypical NF1 cases emphasize phenotypic variability and reinforce the importance of germline testing even in clinically silent presentations.<\/jats:p>","DOI":"10.3390\/jcm15020712","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T12:31:41Z","timestamp":1768480301000},"page":"712","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical and Genetic Characteristics of Pheochromocytoma and Paraganglioma: A Single-Center Experience Including a Rare VHL Variant"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7710-6239","authenticated-orcid":false,"given":"Merve","family":"Korkmaz Yilmaz","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Basaksehir Cam and Sakura City Hospital, University of Health Sciences, 34480 Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozlem","family":"Kandemir Alibakan","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Basaksehir Cam and Sakura City Hospital, University of Health Sciences, 34480 Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5879-6385","authenticated-orcid":false,"given":"Aydeniz","family":"Aydin Gumus","sequence":"additional","affiliation":[{"name":"Department of Medical Genetics, Basaksehir Cam and Sakura City Hospital, University of Health Sciences, 34480 Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2432-9279","authenticated-orcid":false,"given":"Alper","family":"Gezdirici","sequence":"additional","affiliation":[{"name":"Department of Medical Genetics, Basaksehir Cam and Sakura City Hospital, University of Health Sciences, 34480 Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4217-2834","authenticated-orcid":false,"given":"Huseyin","family":"Karatay","sequence":"additional","affiliation":[{"name":"Department of Pathology, Basaksehir Cam and Sakura City Hospital, University of Health Sciences, 34480 Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2918-1776","authenticated-orcid":false,"given":"Serkan","family":"Sari","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Basaksehir Cam and Sakura City Hospital, University of Health Sciences, 34480 Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6305-2957","authenticated-orcid":false,"given":"Tugba","family":"Matlim Ozel","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Basaksehir Cam and Sakura City Hospital, University of Health Sciences, 34480 Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mutlu","family":"Niyazoglu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Basaksehir Cam and Sakura City Hospital, University of Health Sciences, 34480 Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8361-8866","authenticated-orcid":false,"given":"Esra","family":"Hatipoglu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Basaksehir Cam and Sakura City Hospital, University of Health Sciences, 34480 Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(05)67139-5","article-title":"Phaeochromocytoma","volume":"366","author":"Lenders","year":"2005","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"101416","DOI":"10.1016\/j.beem.2020.101416","article-title":"An overview of 20 years of genetic studies in pheochromocytoma and paraganglioma","volume":"34","author":"Buffet","year":"2020","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1097\/HJH.0000000000002438","article-title":"Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: A position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension","volume":"38","author":"Lenders","year":"2020","journal-title":"J. Hypertens."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/MED.0000000000000634","article-title":"Genetics of pheochromocytoma and paraganglioma","volume":"28","author":"Wachtel","year":"2021","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ccell.2017.01.001","article-title":"Comprehensive molecular characterization of pheochromocytoma and paraganglioma","volume":"31","author":"Fishbein","year":"2017","journal-title":"Cancer Cell"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1210\/er.2017-00062","article-title":"New perspectives on pheochromocytoma and paraganglioma: Toward a molecular classification","volume":"38","author":"Crona","year":"2017","journal-title":"Endocr. Rev."},{"key":"ref_7","first-page":"4385","article-title":"Gain-of-function mutations in Wnt pathway genes and MAML3 fusions define an aggressive subtype of paraganglioma","volume":"103","author":"Remacha","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1210\/jc.2014-1498","article-title":"Pheochromocytoma and paraganglioma: An Endocrine Society clinical practice guideline","volume":"99","author":"Lenders","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e1917","DOI":"10.1210\/clinem\/dgac014","article-title":"Universal germline panel testing for individuals with pheochromocytoma and paraganglioma produces high diagnostic yield","volume":"107","author":"Horton","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"19","DOI":"10.15586\/jkcvhl.v8i1.171","article-title":"Germline pathogenic variants identified by targeted next-generation sequencing in pheochromocytoma and paraganglioma","volume":"8","author":"Yalcintepe","year":"2021","journal-title":"J. Kidney Cancer VHL"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1210\/jc.2008-2419","article-title":"Clinically guided genetic screening in a large cohort of patients with pheochromocytoma and\/or paraganglioma","volume":"94","author":"Mannelli","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/ejhg.2010.175","article-title":"von Hippel\u2013Lindau disease: A clinical and scientific review","volume":"19","author":"Maher","year":"2011","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13053-020-00156-9","article-title":"Characteristics and genetic testing outcomes of patients with clinically suspected paraganglioma\/pheochromocytoma syndrome in Singapore","volume":"18","author":"Ting","year":"2020","journal-title":"Hered. Cancer Clin. Pract."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"dgaa502","DOI":"10.1210\/clinem\/dgaa502","article-title":"Sino-European Differences in the Genetic Landscape and Clinical Presentation of Pheochromocytoma and Paraganglioma","volume":"105","author":"Jiang","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"5919","DOI":"10.18632\/oncotarget.27194","article-title":"Mutational profile and genotype\u2013phenotype correlation of non-familial pheochromocytoma and paraganglioma","volume":"10","author":"Albattal","year":"2019","journal-title":"Oncotarget"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"858","DOI":"10.3803\/EnM.2020.683","article-title":"Genetic analysis and clinical characteristics of hereditary pheochromocytoma and paraganglioma syndrome in Korean population","volume":"35","author":"Choi","year":"2020","journal-title":"Endocrinol. Metab."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"bvac105","DOI":"10.1210\/jendso\/bvac105","article-title":"Incidence of pheochromocytoma and paraganglioma over 70 years: A systematic review","volume":"6","author":"Boyle","year":"2022","journal-title":"J. Endocr. Soc."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1530\/ERC-19-0024","article-title":"Genotype-phenotype correlations in pheochromocytoma and paraganglioma: A systematic review and individual patient meta-analysis","volume":"26","author":"Crona","year":"2019","journal-title":"Endocr Relat Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41574-021-00492-3","article-title":"International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers","volume":"17","year":"2021","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrendo.2014.188","article-title":"Paraganglioma and phaeochromocytoma: From genetics to personalized medicine","volume":"11","author":"Favier","year":"2015","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S0022-5347(05)68171-2","article-title":"Pheochromocytoma in von Recklinghausen\u2019s disease (neurofibromatosis type 1)","volume":"162","author":"Walther","year":"1999","journal-title":"J. Urol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"792","DOI":"10.4158\/EP13417.OR","article-title":"Pheochromocytoma in neurofibromatosis type 1: When should it be suspected?","volume":"20","author":"Shinall","year":"2014","journal-title":"Endocr. Pract."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Yonamine, M., Wasano, K., Aita, Y., Sugasawa, T., Takahashi, K., Kawakami, Y., Shimano, H., Nishiyama, H., Hara, H., and Naruse, M. (2021). Prevalence of germline variants in a large cohort of Japanese patients with pheochromocytoma and\/or paraganglioma. Cancers, 13.","DOI":"10.3390\/cancers13164014"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1056\/NEJMoa020152","article-title":"Germ-line mutations in nonsyndromic pheochromocytoma","volume":"346","author":"Neumann","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/joim.12869","article-title":"Genetic testing and surveillance guidelines in hereditary pheochromocytoma and paraganglioma","volume":"285","author":"Muth","year":"2019","journal-title":"J. Intern. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1210\/endrev\/bnab019","article-title":"Personalized management of pheochromocytoma and paraganglioma","volume":"43","author":"Bechmann","year":"2022","journal-title":"Endocr. Rev."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Constantinescu, G., Preda, C., Constantinescu, V., Siepmann, T., Bornstein, S.R., Lenders, J.W.M., Eisenhofer, G., and Pamporaki, C. (2022). Silent pheochromocytoma and paraganglioma: Systematic review and proposed definitions for standardized terminology. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.1021420"},{"key":"ref_28","first-page":"e240111","article-title":"SDHA-related phaeochromocytoma and paraganglioma: Review and clinical management","volume":"31","author":"Kaplan","year":"2024","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Mellid, S., Gil, E., Let\u00f3n, R., Caleiras, E., Honrado, E., Richter, S., Palacios, N., Lahera, M., Galofr\u00e9, J.C., and L\u00f3pez-Fern\u00e1ndez, A. (2023). Co-occurrence of mutations in NF1 and other susceptibility genes in pheochromocytoma and paraganglioma. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.1070074"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/cen.13163","article-title":"Pheochromocytoma and paraganglioma in patients with neurofibromatosis type 1","volume":"86","author":"Gruber","year":"2017","journal-title":"Clin. Endocrinol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1007\/s40618-025-02571-y","article-title":"Pediatric and adolescent von Hippel\u2013Lindau disease: Tumor profiles and genotype\u2013phenotype correlation","volume":"48","author":"Sharma","year":"2025","journal-title":"J. Endocrinol. Investig."},{"key":"ref_32","first-page":"129","article-title":"Hereditary diseases predisposing to pheochromocytoma","volume":"111","author":"Sarkadi","year":"2019","journal-title":"Exp. Suppl."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1530\/ERC-13-0494","article-title":"Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma","volume":"21","author":"Kimura","year":"2014","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/00000478-200205000-00002","article-title":"Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: A clinicopathologic and immunophenotypic study of 100 cases","volume":"26","author":"Thompson","year":"2002","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Su, T., Yang, Y., Jiang, L., Xie, J., Zhong, X., Wu, L., Jiang, Y., Zhang, C., Zhou, W., and Ye, L. (2023). SDHB immunohistochemistry for prognosis of pheochromocytoma and paraganglioma. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1121397"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1677\/ERC-09-0316","article-title":"SDHB loss predicts malignancy in pheochromocytomas\/sympathetic paragangliomas","volume":"17","author":"Blank","year":"2010","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/cge.13055","article-title":"Penetrance of paraganglioma and pheochromocytoma in SDHB mutation carriers","volume":"93","author":"Rijken","year":"2018","journal-title":"Clin. Genet."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41574-023-00926-0","article-title":"Management of pheochromocytoma and paraganglioma in SDHB pathogenic variant carriers","volume":"20","author":"Perrier","year":"2024","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/jmedgenet-2020-107656","article-title":"SDHB variant type impacts phenotype and malignancy","volume":"60","author":"Bayley","year":"2023","journal-title":"J. Med. Genet."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1530\/EC-18-0325","article-title":"Germline SDHB and SDHD mutations in pheochromocytoma and paraganglioma","volume":"7","author":"Huang","year":"2018","journal-title":"Endocr. Connect."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1007\/s00432-017-2397-3","article-title":"SDHB-related pheochromocytoma and paraganglioma: Genotype\u2013phenotype correlations","volume":"143","author":"Jochmanova","year":"2017","journal-title":"J. Cancer Res. Clin. Oncol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/2\/712\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T13:29:02Z","timestamp":1768483742000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/2\/712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,15]]},"references-count":41,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["jcm15020712"],"URL":"https:\/\/doi.org\/10.3390\/jcm15020712","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,15]]}}}